MedTrace Logo

Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis

NCT05733624 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2024-02-05

No results posted yet for this study

Summary

This study is planned to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops(Cyclosporine 0.01%, 0.02%) compared to Restasis(Cyclosporine 0.05%) in Patients with Dry Eye Disease.

Conditions

  • Dry Eye Syndromes

Interventions

DRUG

SCAI-001 0.01% eyedrop

BID for 12weeks

DRUG

SCAI-001 0.02% eyedrop

BID for 12weeks

DRUG

Restasis 0.05% eyedrop

BID for 12weeks

Sponsors & Collaborators

  • SCAI Therapeutics

    lead INDUSTRY

Principal Investigators

  • Lee, MD, PhD · Pusan National Univ. Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-05
Primary Completion
2023-08-23
Completion
2024-02-02

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05733624 on ClinicalTrials.gov